
NRIFF
Healthcare · Drug Manufacturers - Specialty & Generic · $8.7M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 16, 2020 | Time not confirmed | 0.13 | -0.25 | -292.3% |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.19 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.13 | — |
| Mar 31, 2020 | Time not confirmed | -0.05 | -0.11 | -115.8% |
| Dec 31, 2019 | Time not confirmed | -0.03 | -0.03 | -2.7% |
| Sep 30, 2019 | Time not confirmed | -0.28 | 0.08 | +126.9% |
| Jun 30, 2019 | Time not confirmed | -0.74 | -0.39 | +46.8% |
| Mar 31, 2019 | Time not confirmed | -0.87 | -0.49 | +44.1% |
| Dec 31, 2018 | Time not confirmed | 0.03 | -0.30 | -1100.7% |
| Sep 30, 2018 | Time not confirmed | 0.01 | -0.16 | -1740.0% |
| Jun 30, 2018 | Time not confirmed | 0.02 | 0.07 | +242.5% |
| Mar 31, 2018 | Time not confirmed | 0.15 | -0.01 | -107.5% |
Nuvo Pharmaceuticals Inc., a healthcare company, provides prescription and non-prescription products for pain, allergy, and dermatology in the United States, Canada, Europe, and internationally. The company operates through three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis…